Epidemiology of pneumococcal diseases in Spain after the introduction of pneumococcal conjugate vaccines

Enferm Infecc Microbiol Clin (Engl Ed). 2021 Mar;39(3):142-150. doi: 10.1016/j.eimc.2020.02.016. Epub 2020 Mar 27.
[Article in English, Spanish]

Abstract

In Spain, the use of pneumococcal conjugate vaccines (PCVs) has led to a decrease in the incidence of vaccine serotypes causing invasive and non-invasive disease in vaccinated and unvaccinated children and adults. Further, the coverage of most of the resistant serotypes by vaccines resulted in an overall decline in antibiotic resistance. As an undesirable effect, there was an increase in the non-vaccine serotypes causing infection, especially serotypes 1, 7F and 19A after PCV7 and serotype 8 after PCV13 approval, this making the beneficial effect of vaccination less apparent. The inclusion of PCVs in childhood vaccination schedules, its approval for use in healthy adults and the increasing number of serotypes covered by the vaccines in development are strong strategies in the fight against pneumococcal disease. Nonetheless, the epidemiology of Streptococcus pneumoniae infections must be still under surveillance to detect new changes, given the high capacity for recombination and adaptability of this always-surprising microorganism.

Keywords: Factores de transmisión y virulencia; Hábitat; Streptococcus pneumoniae; Streptococcus pneumoniae: Habitat; Transmission and virulence factors.

Publication types

  • Review

MeSH terms

  • Adult
  • Child
  • Heptavalent Pneumococcal Conjugate Vaccine
  • Humans
  • Pneumococcal Infections* / epidemiology
  • Pneumococcal Vaccines*
  • Spain / epidemiology
  • Streptococcus pneumoniae
  • Vaccines, Conjugate

Substances

  • Heptavalent Pneumococcal Conjugate Vaccine
  • Pneumococcal Vaccines
  • Vaccines, Conjugate